Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
A 68-week Phase III study like REDEFINE 1, REDEFINE 2 is evaluating CagriSema in type 2 diabetes patients who are also either obese or overweight. Novo Nordisk’s CEO Lars Fruergaard Jorgensen ...
NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz ... treated with "2.4 mg cagrilintide and 2.4 mg semaglutide once-weekly," the maximum dosage of CagriSema contemplated by the trial, during ...
The company's shares were up 4.2% at 1527 GMT. The CagriSema trial, called REDEFINE-1, is crucial to Novo's drug pipeline as the company loses its first mover advantage with Wegovy and Eli Lilly ...
40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback